In re Palmaz Scientific Inc.

556 B.R. 770, 2016 WL 4778506
CourtUnited States Bankruptcy Court, W.D. Texas
DecidedSeptember 9, 2016
DocketCASE NO. 16-50552-CAG
StatusPublished
Cited by2 cases

This text of 556 B.R. 770 (In re Palmaz Scientific Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Palmaz Scientific Inc., 556 B.R. 770, 2016 WL 4778506 (Tex. 2016).

Opinion

MEMORANDUM OPINION AND ORDER GRANTING, IN PART AND DENYING, IN PART FIRST AND FINAL APPLICATION FOR PAYMENT OF FEES AND REIMBURSEMENT OF EXPENSES BY NORTON ROSE FULBRIGHT US LLP, ATTORNEYS FOR DEBTORS IN POSSESSION (TIME PERIOD: MARCH 4, 2016 — JUNE 10, 2016) (ECF NO. 290)

CRAIG A. GARGOTTA, UNITED STATES BANKRUPTCY JUDGE

Came on to be considered the First and Final Application of Norton Rose Fulbright US LLP for Reimbursement of Ex[772]*772penses as Attorneys for Debtors in Possession from March 4, 2016 — June 10, 2016 (EOF No. 290) (hereinafter “the Application). For the reasons stated herein, the Court finds that the Application is allowed, in part, and denied, in part.

JURISDICTION AND VENUE

The Court has subject matter jurisdiction over this matter under 28 U.S.C. § 1334. This matter is defined as a core proceeding under 28 U.S.C. § 157(b)(2)(A) (administration of the estate) and 28 U.S.C. § 157(b)(2)(B) (allowance or disal-lowance of claims against the estate). Venue is proper under 28 U.S.C. §§ 1408 and 1409. This is a contested matter under Fed. R. Bankr. P. 7052, in which the Court may make findings of fact and conclusions of law. This matter is referred to the Court under the District Court’s Order of Reference.

BACKGROUND

Norton Rose Fulbright US LLP (hereinafter “Applicant”) seeks from the bankruptcy estate, payable as an administrative expense, professional fees of $393,981.00 and reimbursement of expenses of $7,690.94 for a total award of $401,671.94 for the time period March 4, 2016 through June 10, 2016 for representation of debtors-in-possession Palmaz Scientific Inc. (“Palmaz Scientific”), Advanced Bio Prosthetic Surfaces, Ltd. (“ABPS”), ABPS Venture One, Ltd. (“Venture”), and ABPS Management, L.L.C. (“Management”) (collectively, “Debtors”).

Prior to filing of the jointly administered chapter 11 petitions, Palmaz Scientific was a Delaware corporation formed on February 12, 2008, and was owned by over 300 shareholders. Palmaz Scientific had three affiliate companies: ABPS, Venture, and Management. Palmaz Scientific was the 100% member owner of ABPS Management. ABPS Management served as the General Partner and one percent limited partner in ABPS. Palmaz Scientific owned the remaining 99% limited partnership interest in ABPS. Palmaz Scientific owned an 80% member interest in Venture. The other 20% of Venture was owned by Dr. Steve Bailey. .

Debtors were involved in research and development dedicated to the advancement of the technology and science of medical implants. Debtors’ headquarters were in San Antonio, Texas. The research and development operations were in Fremont, California. Together, Debtors owned 256 issued United States and international patents and 182 active United States and international patent pending filings on its technologies, including thin-film technologies and physical vapor deposition process innovations to produce more reliable implantable prosthetic devices. Debtors, however, had not yet created a medical device for mass production. Debtors’ extensive intellectual property portfolio was the foundation for a technology platform with many potential implantable medical devices, including stents that address coronary, peripheral and intracranial indications as well as implantable devices in orthopedic and cosmetic prosthetic specialties. Debtors also owned highly specialized equipment.'

Debtors’ operations had been financed by a series of equity financings, raising capital by selling nearly $50,000,000 in equity interests to fund its operations. When they did experience revenue, Debtors’ sources of revenue were related to joint development agreements or other partnering agreements. Debtors’ are or have been a party to several lawsuits, which are described below:

(1) Harriman v. Palmaz Scientific, Inc., et al. 134th Judicial District, Dallas County, Texas, Cause No. DC-15-12314. Plaintiff Susan E. Harriman sued defendants Palmaz Scientific, Julio Cesar Pal-[773]*773maz, Steven Brett Solomon, Gary Zim-pelman, John Asel, John Does 1-20 and Jane Does 1-20. Defendants Palmaz Scientific, Julio Cesar Palmaz, Steven Brett Solomon filed counterclaims against Susan E. Harriman Defendant (as Third Party Plaintiff). Palmaz Scientific filed third-party claims against Alan Chesler, Ehrenberg Chesler Interests, LLC, Ehrenberg Chesler Securities, Inc., and IMS Securities, Inc.
(2) Ehrenberg, et al. v. Palmaz Scientific, Inc., et al. 162nd Judicial District, Dallas County, Texas, Cause No. DC-15-11994. Plaintiffs Mildred Y. Ehrenberg, Richard Benedikt, M.D., Arie Salzman, M.D., and Plant Family Investments Ltd. sued defendants Palmaz Scientific, Steven B. Solomon and Julio Palmaz, M.D.
(3) Advanced Bio Prosthetics Surfaces Ltd., et al. v Akin Gump Strauss Hauer & Feld, Baker Botts, L.L.P., and Cecil Schenker. 225th District Court, Bexar County Texas, Cause No. 2014-CI-16776. Plaintiffs ABPS, Venture, ABPS Management, Palmaz Scientific, and Dr. Julio Palmaz sued Akin Gump Strauss Hauer & Feld, L.L.P., Baker Botts, L.L.P., and Cecil Schenker for breach of fiduciary duty, fraud, and conspiracy.

In November 2015, Palmaz Scientific issued a Confidential Private Placement Memorandum in an effort to raise additional operational and research funds, but such fundraising did not raise sufficient funds. Palmaz Scientific alleged that its fundraising ability and business operations were disrupted by litigation brought against Palmaz Scientific in Dallas, Texas. Palmaz Scientific brought counterclaims in that litigation asserting that the plaintiffs spread false and disparaging information about Palmaz Scientific. Additionally, the counterclaims assert that false information was intentionally disseminated to current investors, potential business partners, the press, and even federal government authorities — resulting in substantial damages — essentially crippling Palmaz Scientific’s ability to maintain its ongoing operations. In its counterclaims, Palmaz Scientific asserts the defamation irreparably harmed it and caused it millions of dollars in damages.

In light of its inability to raise additional capital, and the additional burden of pending litigation, Debtors concluded that they should sell all or substantially all of their assets in connection with a case under chapter ll.2 Effective January 25, 2016, debtors retained Applicant to represent it in connection with the filing and prosecution of a chapter 11 bankruptcy case.

On March 4, 2016 (“Petition Date”), Debtors filed voluntary petitions commencing the above-captioned voluntary chapter 11 cases. Since the Petition Date, Debtors premised their chapter 11 cases on selling all of Debtors’ assets. In connection therewith, Debtors employed — with Court approval — Gerbsman Partners to assist in marketing the assets to third parties. In addition, Debtors negotiated an agreement for Vactronix Scientific Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Merkle
575 B.R. 704 (W.D. Texas, 2017)
In re Community Home Financial Services, Inc.
571 B.R. 702 (S.D. Mississippi, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
556 B.R. 770, 2016 WL 4778506, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-palmaz-scientific-inc-txwb-2016.